📌 Visit our 4 posters in Exhibit Hall 3 (HCC), covering key insights into BCMA-directed therapies, ASCT outcomes, CAR-T vs BsAb, and maintenance strategies in #MultipleMyeloma. 📝 Poster Presentations: 🔹 Poster ID 580: Real-World Efficacy of BCMA-Directed Therapies after

Proud of our USMIRC News team for putting out so many posters at #Tandem2025 Highlighting this very relevant ❓ of options in BCMA exposed RRMM #mmsm by Jordan Snyder, PharmD, BCOP Al-Ola A Abdallah MD (USMIRC) Prerna Mewawalla Nausheen Ahmed MD Muhammad Umair Mushtaq (Abu Mikael) Hamza Hashmi James Davis, PharmD, BCOP

Our UI Holden Comprehensive Cancer Center #mmsm led BCMA CART manufacturing failure project presented at #Tandem25 . Time from Cytoxan affected successful manufacturing. Limited number of pts with TCE bsAb exposure. Brainchild of Chris Strouse Collab with James Davis, PharmD, BCOP USMIRC News

Hoping to see follow-up and label changes with this poster by Rahul Banerjee, MD, FACP on a ❓I and my patients ask repeatedly - Is 8 week driving restriction post-BCMA CART necessary? #Tandem25 Rahul Banerjee, MD, FACP Kudos for finding ways to answer ❓affecting #QOL in #mmsm

Excited for upcoming Binaytara Foundation's spotlight session covering Best of Hematology and Breast Cancer updates at Des Moines. Can't wait to hear from Hira Shaikh Chris Strouse Nanmeng Yu Grerk Sutamtewagul Binaytara Binay Shah, MD, MHA Dr. Phadke #BTFHemBreast25 #hematology #Oncology

📢 New Publication Alert! Excited to share our latest study in Blood Cancer Journal (IF 12.9) on real-world efficacy & safety of belantamab mafodotin in relapsed refractory multiple myeloma 🔹 ORR: 40% in high-risk, heavily pretreated patients 🔹 EMD linked to poorer outcomes

Great work Rachel DiLeo and Hamza Hashmi

So proud and excited for our trainee Mehndi Dandwani at UI Holden Comprehensive Cancer Center University of Iowa Health Care being selected as fellow of the month Oncology Data Advisor and sharing her journey.

Excited to have the opportunity to talk about #mmsm and connect with fellow Iowan oncologists I have been on phone with plenty of times. Binaytara

Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory sciencedirect.com/science/articl… KU Cancer Center USMIRC News Hira Shaikh Al-Ola A Abdallah MD (USMIRC) Nausheen Ahmed MD

2/ ⚛️ Efficacy in comparison to MonumenTAL-1: The real-world study ORR of 71%, with 51% achieving ≥ VGPR & 25% achieving ≥ CR. This is comparable to the ORR of 70% and 64% observed in the weekly and every other week dosing cohorts of the MonumenTAL-1 trial. The estimated

3/ 🛑Safety: The overall safety profile was similar to MonumenTAL-1, with cytopenias being the most frequent and severe adverse event. A) Dysgeusia was more frequent in the real-world cohort (78%) compared to the MonumenTAL-1 weekly/biweekly cohorts (57%/63%) B) Infections (29%)

5/🤔Impact of Prior Bispecific Antibody Exposure and BCMA-Directed Therapy (BDT): ♾️ Prior exposure to bispecific T-cell engagers (TCEs) was associated with worse outcomes. The study found that patients with prior TCE exposure had a significantly lower ORR (59.2% vs 100%,

7/Prognostic Factors: •Multivariate analysis identified prior bispecific antibody exposure (HR 3.87, p=0.01) & extramedullary disease (EMD) (HR 2.81, p<0.01) as independent factors associated with worse PFS. •🤷‍♂️Inability to meet MonumenTAL-1 eligibility criteria was associated

8/🧱 Limitations: - Retrospective nature - Relatively small cohort size - Potential variability in follow-up periods and supportive care practices across institutions - Limited ability to perform comprehensive multivariate analyses for all outcomes due to the number of events -

Honoured to author the first publication of BloodICT Blood Advances

I could not have come up with a better summary. Excited to share our article on RWE of talquetamab in #mmsm. Also the first publication of BloodICT Blood Advances Al-Ola A Abdallah MD (USMIRC) Nausheen Ahmed MD Muhammad Umair Mushtaq (Abu Mikael) Alma Habib, MD, MS Jordan Snyder Shebli Atrash Chris Strouse Prerna Mewawalla

Hence, limited duration treatment needs to be evaluated for these drugs in #mmsm Al Garfall is leading LimiTEC study which studies limited duration bispecific. Also open at University of Iowa Chris Strouse and Columbia Raj Chakraborty

This is probably the lead takeaway from the study. Unfortunately not all patients can afford a 6 month break between therapies. However, when possible this needs to be prioritised. T cells need a break. And sequencing therapies in #mmsm is becoming a bigger problem.

📢 Excited to share our multicenter study just published in Clinical Lymphoma, Myeloma & Leukemia: “Real-world outcomes of sequential BCMA therapies in RRMM after belantamab” 🔗 clinical-lymphoma-myeloma-leukemia.com/article/S2152-… Shout-out to Hamza Hashmi Racheldileo With: Yue Yin Christopher Strouse